...
首页> 外文期刊>Angewandte Chemie >Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction
【24h】

Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction

机译:靶向menin-mll蛋白蛋白蛋白互动的一流,高效不可逆抑制剂的设计

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The structure-based design of M-525 as the first-in-class, highly potent, irreversible small-molecule inhibitor of the menin-MLL interaction is presented. M-525 targets cellular menin protein at sub-nanomolar concentrations and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL-regulated gene expression in MLL leukemia cells. M-525 demonstrates high cellular specificity over non-MLL leukemia cells and is more than 30 times more potent than its corresponding reversible inhibitors. Mass spectrometric analysis and co-crystal structure of M-525 in complex with menin firmly establish its mode of action. A single administration of M-525 effectively suppresses MLL-regulated gene expression in tumor tissue. An efficient procedure was developed to synthesize M-525. This study demonstrates that irreversible inhibition of menin may be a promising therapeutic strategy for MLL leukemia.
机译:提出了M-525的基于结构的设计作为先进的,高效,不可逆转的小分子抑制Menin-MML相互作用。 M-525针对亚纳摩浓度的细胞Menin蛋白靶向,并在细胞生长抑制中实现低纳米摩尔疗效,并在MLL白血病细胞中抑制MLL调节基因表达。 M-525通过非MLL白血病细胞显示出高细胞特异性,并且比其相应的可逆抑制剂具有比其相应的可逆抑制剂更高的30倍以上。 M-525在络合物中的质谱分析和Co晶体结构与Menin牢固地建立其作用方式。 单一施用M-525有效地抑制肿瘤组织中的MLL调节基因表达。 开发了一种有效的程序来合成M-525。 该研究表明,MLL白血病的不可逆抑制可能是一个有希望的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号